Hepatitis C Articles (HCV)
Epclusa European Commission - SUMMARY OF PRODUCT CHARACTERISTICS
Download the PDF here
European Commission Grants Marketing Authorization for Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
SUMMARY OF PRODUCT CHARACTERISTICS
Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1).
The recommended dose of Epclusa is one tablet, taken orally, once daily with or without food (see section 5.2).
View Older Articles
Back to Top